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Overcoming the plasticity of 
plant specialized metabolism for 
selective diterpene production in 
yeast
Codruta Ignea1,2, Anastasia Athanasakoglou1,2, Aggeliki Andreadelli3, Maria Apostolaki4, 
Minas Iakovides4, Euripides G. Stephanou4, Antonios M. Makris3 & Sotirios C. Kampranis1,2
Plants synthesize numerous specialized metabolites (also termed natural products) to mediate dynamic 
interactions with their surroundings. The complexity of plant specialized metabolism is the result of 
an inherent biosynthetic plasticity rooted in the substrate and product promiscuity of the enzymes 
involved. The pathway of carnosic acid-related diterpenes in rosemary and sage involves promiscuous 
cytochrome P450s whose combined activity results in a multitude of structurally related compounds. 
Some of these minor products, such as pisiferic acid and salviol, have established bioactivity, but 
their limited availability prevents further evaluation. Reconstructing carnosic acid biosynthesis in 
yeast achieved significant titers of the main compound but could not specifically yield the minor 
products. Specific production of pisiferic acid and salviol was achieved by restricting the promiscuity 
of a key enzyme, CYP76AH24, through a single-residue substitution (F112L). Coupled with additional 
metabolic engineering interventions, overall improvements of 24 and 14-fold for pisiferic acid and 
salviol, respectively, were obtained. These results provide an example of how synthetic biology can 
help navigating the complex landscape of plant natural product biosynthesis to achieve heterologous 
production of useful minor metabolites. In the context of plant adaptation, these findings also suggest 
a molecular basis for the rapid evolution of terpene biosynthetic pathways.
A unique feature of plants is their inherent phenotypic plasticity. Being immobile organisms, plants cannot move 
away from unfavorable conditions. As a result, they respond to environmental changes by altering their mor-
phology, physiology and metabolism. Metabolic plasticity, in particular, involves the synthesis of an astonishing 
number of specialized metabolites, also known as natural products, which are responsible for plant defense and 
adaptation, mediating multipurpose interactions among organisms1–5. Plants have developed complex metabolic 
pathways that enable them to rapidly and dynamically change the profile of specialized metabolites produced in 
order to adapt to diverse and fluctuating environmental factors. Many of these compounds have important appli-
cations as pharmaceuticals, flavors, fragrances or biofuels6–8. However, exploitation of plant natural products is 
frequently hindered by metabolic plasticity. Potential pharmacologically or industrially relevant metabolites are 
only produced in minute amounts, under specific conditions or environmental stimuli, or in complex mixtures of 
structurally related compounds. Thus, achieving efficient biotechnological production of compounds of interest 
requires the development of approaches that navigate the complex landscape of plant specialized metabolism to 
bypass the limitations imposed by metabolic plasticity.
The mechanisms underlying plant natural product plasticity rely on the promiscuity of the corresponding bio-
synthetic enzymes. Most enzyme groups involved in specialized metabolism exhibit relaxed substrate or product 
specificity. This is particularly true in the case of terpenoids, the largest class of plant natural products9. Terpene 
synthases use a handful of simple precursors to generate a broad range of terpenoid skeletons. For example, 
γ-humulene synthase synthesizes 52 different sesquiterpenes from farnesyl diphosphate (FPP)10, while several 
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class I diterpene synthases (diTPSs) accept alternative diterpene diphosphate substrates with similar efficiency 
to produce different compounds11–16. Cytochrome P450 monooxygenases (CYPs), key enzymes for terpenoid 
structural diversity, are also quite promiscuous. Several multi-substrate and multi-functional CYPs have been 
identified, including enzymes of the CYP720B subfamily, involved in diterpene resin acids biosynthesis in gym-
nosperms17, 18, and members of the CYP76AH and CYP76AK subfamilies, which participate in carnosic acid 
biosynthesis in sage and rosemary19–22 (Fig. 1) or tanshinone biosynthesis in the Chinese medicinal plant Salvia 
miltiorrhiza23. Achieving efficient production of compounds of interest in a heterologous host may thus require 
the engineering of the enzymes involved to generate dedicated biocatalysts11. The same also applies for the isola-
tion of desirable products from large scale combinatorial biosynthesis efforts16.
Carnosic acid is a potent antioxidant present in high amounts in rosemary and sage24. This diterpenoid is 
synthesized, together with a group of structurally related compounds, through a complex biosynthetic pathway 
(Fig. 1 and ref. 19). Carnosic acid-related diterpene biosynthesis starts from the universal diterpene precursor 
geranylgeranyl diphosphate (GGPP). This is cyclized through the action of class II and class I diterpene synthases 
to the basic labdane-type skeleton of miltiradiene, which is further oxidized to abietatriene (Fig. 1). In the sage S. 
pomifera, the final steps of this pathway involve the enzymatic activity of three CYPs, CYP76AH24, CYP71BE52 
and CYP76AK6. CYP76AH24 is a bifunctional enzyme that catalyzes the synthesis of ferruginol by oxidation 
of abietatriene at C-12 and subsequently adds a second hydroxyl group at position C-11 of ferruginol to pro-
duce 11-hydroxy-ferruginol19. The same enzyme accepts additional substrates, such as miltiradiene and manoyl 
oxide, to produce 11-keto-miltiradiene (Fig. 1 and ref. 19) and 11β-hydroxy-manoyl oxide (Fig. 1 and ref. 20), 
respectively. CYP71BE52 hydroxylates ferruginol at C-2α to produce salviol19, a compound also found in the 
bioactive extract of S. miltiorrhiza roots25, 26. Additional biosynthetic steps involve oxidation of ferruginol and 
11-hydroxy-ferruginol to produce pisiferic acid and carnosic acid (Fig. 1). Pisiferic acid, which is an antibacte-
rial27–29 and antifungal30, 31 agent, is produced from ferruginol by successive oxidations at position C-20 catalyzed 
by CYP76AK619 (Fig. 1). However, the same enzyme is also responsible for the synthesis of carnosic acid from 
11-hydroxy-ferruginol (Fig. 1). This highly complex pathway organization is an important hurdle in the study 
or exploitation of individual compounds in the group, particularly those present in lower abundance, as their 
isolation from a natural source is highly challenging. Transplanting the pathway leading to specific compounds in 
Figure 1. Diagrammatic representation of the biosynthetic pathway of labdane-type diterpenes and its 
reconstruction in yeast. Starting from the common precursor geranylgeranyl diphosphate (GGPP), different 
class II diTPSs synthesize copalyl diphosphate (CPP) or 8-hydroxy-copalyl diphosphate (8-OH-CPP). 
Miltiradiene synthase (MilS) can accept either CPP or 8-OH-CPP to produce miltiradiene or manoyl oxide, 
respectively (refs 11, 20). Subsequently, the promiscuous enzyme, CYP76AH24, oxidizes miltiradiene, 
abietatriene, ferruginol and manoyl oxide, to synthesize the corresponding oxygenated molecules in position 
C-12 or C-11 (the biosynthetic pathways are described in details in the main text). Different CYPs perform 
additional oxidations to produce carnosic and/or pisiferic acid (CYP76AK6), or salviol (CYP71BE52). Arrows 
describe the fluxes through the yeast reconstructed pathway before (blue arrows) or after engineering (red 
arrows) for the specific production of pisiferic acid or salviol (Figure produced using ChemDraw Professional 
15.1 and Microsoft Powerpoint).
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a heterologous host is a viable alternative, but the promiscuity of the enzymes involved, essential for maintaining 
the plasticity of the natural system, is limiting.
In this report, we initially engineered yeast cells for the production of carnosic acid and achieved significant 
improvement in yield compared to our previous efforts19. Still, in the improved system, production of the phar-
macologically interesting minor products pisiferic acid and salviol was limited and always accompanied by high 
levels of undesirable by-products. To enable production of these compounds, we set out to redirect the pathway 
away from carnosic acid (Fig. 1). Using protein engineering, we altered the specificity of a central enzyme in 
this biosynthetic pathway, CYP76AH24. A single amino acid substitution restricted the substrate specificity of 
CYP76AH24 and gave rise to a dedicated ferruginol synthase. Using this CYP variant in yeast, we achieved the 
complete biosynthetic shift from carnosic acid to pisiferic acid and we improved the specificity of salviol syn-
thesis by reducing the undesirable by-products 11-keto-miltiradiene and 11-hydroxy-ferruginol. These results 
provide an example of how protein and metabolic engineering can be combined to overcome the plasticity of 
plant specialized metabolism for the heterologous production of useful metabolites that are only produced in 
minor amounts in the plant.
Results
Optimization of carnosic acid production in yeast. In our previous efforts, we developed a modular 
yeast diterpene production platform to facilitate biosynthetic pathway elucidation through rapid screening of 
candidate genes obtained from transcriptomic analysis19, 21. In this platform, described diagrammatically in Fig. 2 
panel a, module M1 is responsible for GGPP synthesis, module M2 (consisting of two submodules, M2a and 
M2b) includes the steps leading to the formation of the basic terpene scaffold, and module M3 encompasses the 
events achieving the decoration/modification of the basic skeleton. In the configuration used for carnosic acid 
pathway elucidation19, M1 employed a yeast farnesyl diphosphate synthase variant (Erg20p(F96C)) that functions 
as a highly efficient GGPP synthase32. Submodule M2a, responsible for copalyl diphosphate (CPP) formation, 
involved S. fruticosa copalyl diphosphate synthase (SfCDS), and submodule M2b, responsible for terpene cycli-
zation, used S. pomifera miltiradiene synthase (SpMilS) to convert CPP to miltiradiene. In M3, terpene oxidation 
events were catalyzed by various CYPs (M3a), assisted by a cytochrome P450 reductase (CPR; M3b) (Fig. 2, 
panel a).Strain AM119-4 (Table 1), engineered for efficient production of oxidized diterpenes20, was employed as 
chassis. In this configuration, carnosic acid titer reached 1 mg/L of yeast culture19.
To improve carnosic acid production, a series of modifications were introduced in this platform. To facili-
tate metabolic channeling, the starting configuration employed a fusion between the M1 and M2a specific parts 
(Erg20p(F96C) and SfCDS). This fusion was based on a linker of three Gly-Ser repeats (3xGS) between the two 
partners19. Previous studies have shown that the length of the linker may influence the efficiency of substrate 
channeling and fusion protein stability, impacting heterologous production of target compounds33. To optimize 
linker length, we constructed and tested two fusions with linkers of different size. One containing five GS repeats 
(SfCDS-5xGS-Erg20p(F96C)) and one containing the GSG tripeptide (SfCDS-GSG-Erg20p(F96C)). Compared 
to the original 3xGS fusion, carnosic acid production in yeast cells engineered to express the two new fusion 
Figure 2. Depiction of the engineered yeast platform for production of carnosic acid-related diterpenes. The 
modular yeast platform previously developed in AM119-4 strain (panel a, light grey background; ref. 20) was 
optimized for carnosic acid production in three steps, including engineering of a shorter linker (GSG) between 
the M1 and M2a parts (panel b), chromosomal integration of SpCytb5 in strain AM141 (dark grey background) 
(panel c), and modulation of CPR expression by switching from the strong inducible promoter PGAL1 (dark 
orange) to the weaker constitutive PTPI1 promoter (light orange) (panel d).
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proteins was slightly reduced in the case of the 5xGS linker, but improved by 2-fold when the shorter GSG linker 
was used (Fig. 2 panel b, Fig. 3A and Table 2).
Previous studies have shown that the efficiency of some CYP-catalyzed oxidations in yeast is improved by the 
presence of cytochrome b5 (Cytb5)34–36 that may function as a partner or modulator in CYP/CPR complexes. To 
evaluate the effect of Cytb5 in carnosic acid biosynthesis in yeast, we searched our S. pomifera trichome-specific 
transcriptomic dataset21 and identified one SpCytb5 transcript present in high abundance (indicated by its 
FPKM value). This gene (DNA sequence in Supplementary Information) was amplified from S. pomifera 
trichome-derived cDNA and integrated at the 3′-end of the YAL065C locus of strain AM119-420 under the 
control of the strong constitutive promoter PTDH3, generating strain AM141 (Table 1). Expression of SpCytb5 in 
AM141 resulted in approximately 4-fold yield improvement over the parental strain, AM119-4 (Fig. 2 panel c and 
Fig. 3B, Table 2), reaching 9.15 mg/L carnosic acid.
Strain Genotype Source
AM119-4
(Mat a/α, PGal1-HMG2(K6R)::HOX2, ura3, trp1, his3, PTDH3-HMG2(K6R)X2-::leu2 
ERG9/erg9, ubc7/UBC7, ssm4/SSM4, mct1/MCT1, whi2/WHI2, gdh1/GDH1, PTDH3-
HEM3::FLO5.
ref. 20
AM141
Mat a/α, PGal1-HMG2(K6R)::HOX2, ura3, trp1, his3, PTDH3-HMG2(K6R)X2-::leu2 ERG9/erg9, 
ubc7/UBC7, ssm4/SSM4, mct1/MCT1, whi2/WHI2, gdh1/GDH1, PTDH3-HEM3::FLO5, PTDH3-
SpCytb5::3′YAL065C
this study
Table 1. List of S. cerevisiae strains used.
Figure 3. Optimization of carnosic acid production in yeast. (A) Production of carnosic acid was evaluated 
using linkers of different size between the M1 and M2a module-specific parts. 2-fold improvement was achieved 
using the GSG tripeptide linker (M1-GSG-M2a). (B) Expression of SpCytb5 from a single chromosomal 
copy (strain AM141) further increased the CA yield by 4-fold. (C) Balancing the CPR/SpCytb5 expression 
further increased carnosic acid production to 18 mg/L. CPR and SpCytb5 were expressed from chromosomal 
integration (::3′YAL065C), from a low copy-number plasmid (ARS/CEN), or from a high copy number plasmid 
(2μ), under the control of constitutive (PTPI1 or PTDH3) or inducible (PGAL1 or PGAL10) promoters of different 
strength (PTPI1 – medium or PTDH3, PGAL1 or PGAL10 – strong).
strain protein expressed linker
carnosic acid yield 
(mg/L of culture)
fold improvement 
(from previous step)
fold improvement 
(total)
AM119-4 CYP76AH24wt 3XGS 1.02 ± 0.08 — —
AM119-4 CYP76AH24wt GSG 2.18 ± 0.15 2.13 2.13
AM141 CYP76AH24wt GSG 9.15 ± 0.50 4.19 9.33
AM141 CYP76AH24wt + CPR(PTPI1) GSG 18.09 ± 0.82 1.97 17.73
Table 2. Overview of carnosic acid yield improvement.
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High-level expression of cytochrome P450 reductase (CPR) may lead to inefficient interactions with its CYP 
partners resulting in significant leak of electrons and an overall increase of oxidative stress in engineered het-
erologous production systems37. On the other hand, low CPR expression may not provide CYP enzymes with 
adequate reducing equivalents for efficient function. Since CPR expression could be a rate-limiting factor for 
CYP activity, we set out to balance co-expression of CPR, CYPs and Cytb5 in carnosic acid-producing yeast cells. 
To enable introduction of a new part into the existent modular platform, we initially generated a pESC-based 
construct expressing two CYPs (CYP76AH24 and CYP76AK6) under tryptophan selection. Subsequently, we 
engineered and analyzed AM141 derived yeast cells expressing CPR and Cytb5 from a combination of high and 
low copy number plasmids (containing the 2μ or ARS/CEN origin of replication, respectively) under promoters 
of varying strength. CPR was evaluated using the strong, inducible PGAL1 promoter, the strong constitutive PTDH3 
promoter, or the medium strength constitutive promoter PTPI1 (Fig. 2 panel d and Fig. 3C, Table S1). Cytb5 expres-
sion was varied between a high copy number plasmid (pESC) driven by the strong inducible promoter PGAL10, 
a single chromosomal integration under the PTDH3 promoter, or from a low copy number plasmid (pYX143) 
under the constitutive promoter PTPI1 (Fig. 2 panel d and Fig. 3C, Table S1). The highest production of carnosic 
acid, reaching 18 mg/L (almost 2-fold improvement over the previous intervention), was achieved in yeast cells 
expressing SpCytb5 only from a single chromosomal integration (AM141 strain) and CPR from a low copy num-
ber plasmid under the control of the PTPI1 constitutive promoter (Fig. 2 panel d and Fig. 3C, Tables 1 and 2). The 
growth rate of all strains tested in Fig. 3 was similar, suggesting that the observed titer improvement was not due 
to higher biomass yield achieved as a result of lowering the metabolic burden of CPR or SpCytb5 expression.
Engineering the specificity of CYP76AH24. Despite achieving significant improvement in carnosic acid 
titers using these interventions, production of the minor metabolites pisiferic acid and salviol was still limited. 
Like carnosic acid, pisiferic acid is also formed by oxidation of C-20 by CYP76AK6. For pisiferic acid synthe-
sis, CYP76AK6 acts on ferruginol, while for carnosic acid it acts on 11-hydroxy-ferruginol, both produced by 
CYP76AH24. However, when both CYP76AK6 and CYP76AH24 are present, yeast cells produce almost exclu-
sively carnosic acid (carnosic acid/pisiferic acid ratio 10:1; Fig. 4A, Table S2, and ref. 19). This is because the 
ability of CYP76AK6 to catalyze oxidation of 11-hydroxy-ferruginol compared to ferruginol is different, favor-
ing carnosic acid biosynthesis19. Similarly, when salviol production was reconstructed using CYP76AH24 and 
CYP71BE52 in the improved yeast platform described above, salviol titers reached 1.1 mg/L but salviol was not 
the main product (Fig. 4B, Table S2). Due to the ability of CYP76AH24 to also oxidize C-11 of miltiradiene and 
ferruginol, salviol production in this system was dominated by 13.5 mg/L of 11-keto-miltiradiene and around 
20 mg/L of 11-hydroxy-ferruginol (Fig. 4B, Table S2).
Aiming to engineer efficient production of the specific minor compounds, pisiferic acid and salviol, we under-
took a protein engineering effort to overcome the plasticity of the carnosic acid pathway by altering the cata-
lytic specificity of key enzymes in the pathway. Examination of the complex biosynthetic scheme of carnosic 
acid-related diterpenes (Fig. 1) reveals that although CYP76AK6 catalyzes the synthesis of both carnosic acid 
and pisiferic acid with kinetic parameters favoring carnosic acid biosynthesis19, this enzyme does not present an 
immediate target for mutagenesis for directing the flux of the pathway towards pisiferic acid. Rather, CYP76AH24 
presents a better point for intervention, as it lies in a central node of the pathway after which this bifurcates to 
an 11-hydoxy-ferruginol branch leading to carnosic acid and a ferruginol branch that leads to pisiferic acid or 
salviol (Fig. 1). CYP76AH24 is a bifunctional enzyme producing the precursor for both these branches, and if 
it could be tailored to produce predominantly ferruginol this would redirect the pathway towards the desirable 
minor compounds.
Following extensive structural template search, five models of CYP76AH24 were built, based on the structural 
data of CYP17A1 (PDB ID: 4nkv), CYP2A6(N297Q/I300V) (PDB ID: 2pg7), CYP17A2 (PDB ID: 4r21), CYP3A4 
(PDB ID: 4ny4), and CYP2A13 (PDB ID: 3t3s), using Swiss-model (swissmodel.expasy.org). The model based 
on CYP17A1 displayed the best quality scores (QMEAN = −2.34, GQME = 0.65) and was selected for further 
analysis (Fig. 5A). It was assumed that to achieve the desired shift in regio-specificity, only a small change in 
Figure 4. Redirecting biosynthetic fluxes towards specific compounds by engineering CYP76AH24 specificity. 
(A) Biosynthetic shift from carnosic acid to pisiferic acid production in yeast cells. (B) Abolishing undesirable 
production of 11-keto-miltiradiene and 11-hydroxy-ferruginol production in yeast to favor biosynthesis of 
salviol.
www.nature.com/scientificreports/
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the positioning of the substrate that takes C-11 further away from the heme-bound oxygen, but retains optimal 
positioning of C-12, would be sufficient. The amino acids that line the active site cavity were mapped and three 
residues located at key positions shaping the active-site contour where highlighted. These were F112, V296 and 
F477. Aiming to make only minor adjustments to the geometry of the active site, a minimal mutant library was 
constructed by substituting each of these amino acids with hydrophobic residues of somewhat larger or smaller 
size. Thus, F112 was substituted with H or L, V296 with F, L or I, and F477 with H or L.
Development of a dedicated ferruginol synthase. The resulted library was evaluated in yeast cells 
producing miltiradiene or manoyl oxide and the results of the screening are summarized in the bar chart pre-
sented in Fig. 5B. Two variants exhibiting enhanced oxidation of abietatriene at C-12 were identified. These two 
mutations, F112L and V296L, were also found to improve the substrate specificity of CYP76AH24 by suppressing 
its ability to oxidize different other substrates, including ferruginol, miltiradiene and manoyl oxide, at position 
C-11. When expressed in yeast cells, CYP76AH24(V296L) produced 1.5 times more ferruginol, but 8-fold less 
11-hydroxy-ferruginol and 20-fold less 11β-hydroxy-manoyl oxide than the wild-type enzyme (Fig. 6A and B, 
Table S2). No oxidation of miltiradiene was detected in yeast cells using this mutant. CYP76AH24(F112L) cata-
lyzed ferruginol production in yeast 2 times more efficiently than the wild-type enzyme, while production of 
11-hydroxy-ferruginol was abolished (Figs 4A and 6A, Table S2). Moreover, this variant did not oxidize milti-
radiene or manoyl oxide in the yeast system (Fig. 6A and B). In vitro enzymatic assays using yeast microsomal 
preparations of CYP76AH24(V296L) and CYP76AH24(F112L) with ferruginol or manoyl oxide as substrate 
and NADPH as co-factor confirmed the reduced ability (or complete lack of) of these variants to oxidize the 
provided substrates (Fig. 6A and B). Kinetic analysis of the oxidation of abietatriene by CYP76AH24(V296L) 
and CYP76AH24(F112L) revealed biocatalysts with improved activity than the wild-type enzyme (Fig. 6C and 
Table 3).
Establishing specific pisiferic acid and salviol production in yeast cells. We analyzed the effect 
of the identified variants on salviol and pisiferic acid production in yeast. For pisiferic acid, cells expressing 
CYP76AH24(V296L) or CYP76AH24(F112L) were co-transformed with the second CYP involved in carnosic 
acid pathway, CYP76AK6. In both cases, the product profile of the engineered yeast cells revealed a shift towards 
pisiferic acid formation (Table S2 and Fig. 4A). In the case of CYP76AH24(V296L), this shift was smaller and 
carnosic acid remained as a main product, suggesting that the low amounts of 11-hydroxy-ferruginol produced 
by CYP76AH24(V296L) were sufficient to sustain significant levels of carnosic acid, presumably due to the pref-
erence of CYP76AK6 for this substrate19. However, when CYP76AH24(F112L) was used (Fig. 6A), carnosic acid 
production was completely abolished (Fig. 4A). Thus, the CYP76AH24(F112L) variant enabled the complete shift 
from carnosic acid to pisiferic acid production in yeast. Coupled with the metabolic interventions described for 
the optimization of carnosic acid production in yeast, final pisiferic acid titers reached 2.65 mg/L, which repre-
sents a total improvement of 24-fold over the basic strain (Table S2).
For salviol production, cells expressing CYP76AH24(V296L) or CYP76AH24(F112L) were co-transformed 
with the ferruginol 2α-hydroxylating enzyme CYP51BE52. Using both variants, a noticeable improvement 
in salviol titers was observed (Fig. 4B and Table S2). In the case of CYP76AH24(V296L), although low levels 
of ferruginol and miltiradiene oxidation at C-11 could still be observed, suppression of these side pathways 
increased salviol yields by almost 3.5-fold (Fig. 4B and Table S2). However, when CYP76AH24(F112L) was used, 
11-hydroxy-ferruginol and 11-keto miltiradiene production was completely abolished and the salviol titer was 
improved significantly, reaching ~15 mg/L and a total of 14-fold improvement from the initial yield (Table S2 and 
Fig. 4B).
Figure 5. Engineering CYP76AH24 specificity. (A) Model of CYP76AH24 showing the residues selected for 
mutagenesis (F112, V296 and F477). Graphic produced by DeepView (Swiss-PdbViewer). (B) Product profile 
of selected mutants. Products include: ferruginol (green), 11-hydroxy-ferruginol (red) and 11β-hydroxy-
manoyl oxide (blue). Two variants, F112L and V296L, showed substrate selectivity and improved catalytic 
activity. Product titers for each of the three substrates were normalized based on the corresponding wild-type 
CYP76AH24 yield listed in Table S1 and considered as 100%.
www.nature.com/scientificreports/
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Discussion
Many plant specialized metabolites can be obtained in sufficient amounts by extraction from their natural sources 
(e.g. carnosic acid, artemisinin, tanshinones, forskolin). In this case, the molecule of interest is often also the 
main product of the corresponding biosynthetic pathway. However, many more compounds with potential indus-
trial application are only produced in low amounts or in complex mixtures. Obtaining access to these molecules 
Figure 6. Engineering the specificity of CYP76AH24. (A) Evaluation of CYP76AH24 variants in miltiradiene 
producing yeast cells (V296L (teal) and F112L (pink) versus wt (black)). (B) Evaluation of the same 
CYP76AH24 variants in manoyl oxide producing yeast cells. (C) Steady-state kinetic analysis of the oxidation of 
abietatriene by CYP76AH24 variants V296L (open squares) and F112L (open circles) versus wt (closed circles).
Oxidized 
carbon Substrate Enzyme kcat (min−1) KM (μM)
kcat/KM (× 
103 min−1 M−1) Source
C-12 abietatriene
CYP76AH24 5.51 ± 0.71 20.62 ± 6.12 267.2 ref. 19
CYP76AH24(V296L) 6.24 ± 0.93 20.03 ± 6.97 311.5 this study
CYP76AH24(F112L) 9.69 ± 1.31 15.67 ± 5.53 618.4 this study
C-11 ferruginol CYP76AH24 6.11 ± 0.45 45.84 ± 9.37 133.3 ref. 19
C-2α ferruginol CYP71BE52 0.04 ± 0.002 3.96 ± 0.72 10.1 ref. 19
C-20 ferruginol CYP76AK6 1.43 ± 0.21 20.81 ± 7.76 68.7 ref. 19
Table 3. Kinetic parameters of the engineered CYP76AH24 variants.
www.nature.com/scientificreports/
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requires navigating through the chemical complexity created by the inherent biosynthetic plasticity of second-
ary metabolism. The two molecules studied in this work, pisiferic acid and salviol, have been reported to have 
interesting biological properties but their limited availability prevented further characterization. Pisiferic acid, 
was found to have antibacterial and antifungal properties30, 31, while salviol, found in the bioactive extract of S. 
miltiorrhiza roots25, 26, has not yet been evaluated for its biological properties. However, several other compounds 
also found in the same extract, such as tanshindiol B and C or tanshinol, that had for long been overlooked due 
to their low abundance, have recently been found to have potent bioactivity38–40. Establishing pisiferic acid and 
salviol production in yeast will allow the thorough evaluation of their biological activity and the synthesis of 
derivatives.
Efforts in engineering microorganisms for the production of high-value terpenoids have achieved significant 
yield improvements by enhancing precursor flux, rerouting specific endogenous pathways, or balancing enzyme 
levels in the engineered pathway19, 41, 42. However, biosynthetic enzyme properties, such as low catalytic activity 
towards desired substrates or functional promiscuity resulting in branched pathways and reduced metabolic flux, 
frequently hamper metabolic engineering efforts. Pioneering work by Leonard and co-workers showed that com-
bining protein and metabolic engineering can address these challenges43. By engineering functional mutations in 
two key enzymes, the GGPP synthase and levopimaradiene synthase (LPS), a 2600-fold improvement in levopi-
maradiene yield was achieved. A main challenge in production of complex terpenoids is the requirement of mod-
ifying enzymes, such as CYPs. Previous protein engineering efforts of CYP enzymes include the improvement 
of regio-, stereo- and chemoselectivity of CYP102A1 towards different terpene substrates including limonene 
and valencene44, the identification of a critical residue for the second oxidation step of amorpha-4,11-diene by 
CYP71AV145, and the change of regio-selectivity of CYP720B1 towards miltiradiene11.
This study is the first example of engineering the specific production of minor pathway products. Using a 
protein engineering approach, we limited the promiscuity of CYP76AH24, the enzyme residing at the branching 
point of carnosic acid, pisiferic acid and salviol biosynthesis (Fig. 1). Two mutations, V296L and F112L, were 
identified to reduce or abolish, respectively, the ability of the enzyme to catalyze oxidation at C-11, achieving the 
biosynthetic shift from 11-hydroxy or catechol-type compounds to 12-hydroxy-type compounds. Introducing 
these variants into yeast enabled production of the minor compound pisiferic acid and improved production 
of salviol by avoiding the draining of precursors by the formation of undesirable side-products. Thus, protein 
engineering can be combined with metabolic engineering to facilitate steering through the complex landscape of 
plant specialized metabolism.
Even in the improved yeast strains, significant accumulation of ferruginol is observed (Table S2). Kinetic 
analysis shows that this is likely due to the lower catalytic efficiency of CYP76AK6 and CYP71BE52 compared to 
CYP76AH24 (Table 3; compare the reaction of CYP76AH24 with abietatriene with the oxidation of C-20 or C-2 
of ferruginol by CYP76AK6 or CYP71BE52, respectively). These parameters have been determined using yeast 
microsomal preparations of the three CYPs and could reflect the different efficiency of these CYPs in the yeast 
system. In the plant, accumulation of ferruginol is not observed21, suggesting that in this environment either the 
specific activity of these CYPs are different, or the relative levels of the three enzymes are adjusted for optimal 
pathway function. In this sense, further improvement of the current yeast platform could involve balancing of the 
CYP levels using variable promoter strength or gene copy number.
Our results reveal that a single-residue substitution (V296L or F112L) in the key enzyme CYP76AH24 is suffi-
cient to shift the output of the whole pathway from carnosic acid to pisiferic acid or salviol. In the context of plant 
adaptation, these findings suggest a molecular basis for the rapid evolution of terpene biosynthetic pathways in 
response to environmental cues. Mechanistically, the change in specificity observed in the present study requires 
only a minor flip or rotation of the substrate in order to position C-11 further away from the heme center while 
maintaining C-12 in proximity. Indeed, the two identified mutations (V296L or F112L) are predicted to have a 
relatively small impact on the active site contour. Interestingly, they can be achieved with a single-nucleotide 
substitution. Similar one-residue specificity switches have been reported for several terpene synthases46–48 and 
CYPs11, 22, 44, 45. Taken together, these observations suggest that a change in a single amino acid, close or even 
possibly further away from the substrate binding site, can result in a sufficient alteration in geometry or dynamics 
to achieve a significant change in regio-specificity. It can be envisioned that following a gene duplication event, 
a limited number of nucleotide substitutions would be sufficient to rapidly evolve a new biosynthetic activity in 
response to a change in the environment. If this enzyme sits in a central node, such as CYP76AH24 in this case, 
the outcome could redirect the whole pathway towards a new set of structurally related compounds. Thus, this 
synthetic biology approach highlights the genetic and molecular mechanisms of the phenotypic plasticity of plant 
natural products biosynthesis and opens up the way of controlling inherent traits for the selective production of 
high-value compounds.
Materials and Methods
Yeast media. Complete Minimal (CM) medium, composed of 0.13% (w/v) dropout powder (all essential 
amino acids), 0.67% (w/v) Yeast Nitrogen Base w/o AA (Y2025, US Biologicals) and 2% D-( + )-glucose monohy-
drate (16301, Sigma) was used for cultivation of yeast cells. For galactose-based medium, glucose was substituted 
with 2% D-( + )-galactose (G0625, Sigma) and 1% raffinose pentahydrate (R1030, US Biological).
Chemicals and enzymes. Standard compounds carnosic acid (Fluka, 91209) and sclareol (VIORYL SA. 
Athens, Greece) were used. Other standards, such abietatriene, miltiradiene, pisiferic acid and salviol were 
obtained from our in-house collection, isolated from natural sources and characterized by NMR analyses. PCR 
amplifications were performed using Phusion High-Fidelity DNA polymerase (New England BioLabs, M0530) 
and MyTaq DNA polymerase (BIO-21105, Bioline). Restriction enzymes from New England BioLabs were used 
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for cloning purposes. NucleoSpin Plasmid Kit (740588, Macherey-Nagel) was used for plasmid DNA purification. 
QIAquick Gel Extraction Kit (#28704, Qiagen) was used for gel extraction and DNA purification.
Gene cloning and expression vectors. Cloning of Salvia pomifera cytochrome b5. The open reading 
frame of Cytb5 was amplified from S. pomifera glandular trichome cDNA using primers SpCypB5-BamHI and 
SpCypB5-XhoI (Table S3) which incorporated BamHI and XhoI flanking restriction sites at the 5′ and 3′ of the 
ORF, respectively. The PCR product was purified and cloned into pCRII-TOPO TA, according to the manufac-
turer’s instructions (Invitrogen). For expression from low copy number vector under the constitutive promoter 
PTPI1, the ORF of SpCytb5 was digested with BamHI and XhoI from pCRII-TOPO vector and ligated to pYX143 
(PTPI1, LEU2, cen) digested with the same enzymes. For expression from high copy number plasmid under the 
strong inducible promoter PGAL10, the SpCytb5 ORF was amplified from the pCRII-Topo vector using primers 
Cytb5-NotI-5 and Cytb5-SacI-3 (Table S3) to introduce 5′-NotI and 3′-SacI flanking restriction sites. The PCR 
product was purified and cloned into the pCRII-TOPO TA and subsequently digested with NotI and SacI and 
ligated to pESC-Leu and pESC-LEU/CPR2 vectors (Agilent Technologies) linearized with NotI and SacI.
Construct pYX143/CPR2. The ORF of Populus trichocarpa NADPH-cytochrome P450 reductase 
(XM_006381734) was PCR amplified from plasmid pESC-LEU/CPR2-PtAO kindly provided by Prof. J. 
Bohlmann (University of British Columbia, Canada) and primers CPR2-MfeI and CPR2-XhoI (Table S3) which 
incorporated MfeI and XhoI flanking restriction sites at the 5′ and 3′ of the ORF respectively. The PCR product 
was purified and cloned into the pCRII-TOPO TA. The insert was digested with MfeI and XhoI and ligated to 
pYX143 (PTPI1, LEU2, cen) digested with EcoRI and XhoI. For expression from a high copy number plasmid under 
the strong constitutive promoter PTDH3, the CPR2 insert digested with MfeI and XhoI was ligated into pWTDH3 
digested with EcoRI and XhoI.
Cloning M1-M2a fusions with different GS linkers. The constructs pYES/SfCDS-ERG20(F96C) containing dif-
ferent GS linkers were generated as previously described19 using primers SfCDS-BamHI-5 and SfCDS-5xGS-MfeI 
or CDS-GSG-MfeI (Table S3).
Cloning M3a and M3b into pESC-Trp vector. CYP76AK6 was PCR amplified from pESC-Leu::CPR2-CYP76AK6 
construct19 using primers Sp76-5-BamHI and Sp76-5-SalI (Table S3) which incorporated BamHI and SalI 
restriction sites. Following PCR product purification and TOPO cloning, the insert digested with BamHI and 
SalI was ligated into pESC-Trp vector (Agilent Technologies) linearized with the same enzymes. This clon-
ing strategy introduced CYP76AK6 under the control of PGAL1 promoter. CYP76AH24 was digested from 
pESC-Leu::CPR2-CYP76AH24 construct19 using EcoRI and NotI restriction enzymes and ligated into the previ-
ously generated construct pESC-Trp::CYP76AK6 liniarized with EcoRI and NotI to allow gene expression from 
PGAL10 promoter.
Generation of AM141 strain. To develop the yeast integration cassette overexpressing the S. pomifera 
Cytb5, the ORF was excised from pCRII/SpCypB5 using BamHI and XhoI, and ligated to COD7 plasmid49 line-
arized in the same manner. The integration cassette COD7/Sp Cytb5 was PCR amplified using primers YAL065C-
5COD7 and YAL065C-3COD7 (Table S3) which target the cassette to the 3′UTR of YAL065C gene. The 
purified PCR fragment was transformed into the AM119-4 yeast strain and successful integration was selected 
in glucose-CM plates lacking histidine. Proper integration was validated by PCR on genomic DNA isolated from 
several growing colonies using primers YAL065C UP (Table S3) which is located at the upstream genomic region 
and TDH3-R conf which binds on the integration cassette.
Mutagenesis. Site-directed mutagenesis of CYP76AH24 was performed as described in ref. 50 using the 
Quickchange method (Agilent). Introduction of nucleotide changes were performed by the degenerate primers 
described in Table S3.
Yeast strain cultivation, terpene quantification, and extraction from yeast cells. Yeast cells were 
cultivated as previously described11. Cultures grown until OD600 = 0.7–1 were switched to galactose-raffinose 
based selective growth medium (10 mL) for expression of the SpCDS-Erg20p(F96C) fusion, CPR2, Cytb5 and 
CYP76AH24, CYP76AK6 or CYP71BE52 under the galactose-inducible promoters PGAL1 or PGAL10. For produc-
tion, cultures were cultivated for 2 days. Terpene extraction was performed by 10% dodecane overlay or solvent 
(pentane or ethyl acetate) extraction using aliquots of 1 mL cultures. For GC-MS analysis of the oxygenated diter-
penoids, carnosic acid, pisiferic acid and salviol, solvent extracts were derivatized prior to GC-MS analysis using 
the following procedure described in ref. 19. The compounds produced were quantified by GC-FID analysis of 
the solvent extracts, as described in ref. 46.
Microsomal protein preparation and cytochrome P450 quantification. Yeast cultures of 250 mL 
were used to prepare microsomal proteins as previously described51. An additional final ultracentrifugation step at 
100,000 g for 60 min was performed. The quantification of CYPs was carried out as described by Omura and Sato52, 
by measuring the spectroscopic difference at 450 nm resulting from the binding of CO to the reduced form of CYP 
enzymes. The extinction coefficient 91 mM−1 cm−1 was used. For background correction, microsomal preparations 
from cells carrying CPR2 but an empty vector with respect to CYP genes were used (negative control).
In vitro enzymatic assay and kinetic analysis. The kinetic parameters of the CYP76AH24 variants were 
determined as previously described11 using varying concentrations (1–75 μM) of each substrate. The enzymatic 
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reactions were incubated with mild shaking at 30 °C for 3 h and terminated by extraction with 100 μL of decane 
or ethyl acetate containing 10 μg/mL sclareol as internal standard. Extracts (2 μL) were analyzed by GC-MS. All 
assays were carried out in duplicates.
GC-MS analysis was carried on a DB-5 column using helium as a carrier gas with a constant velocity of 40 cm/
sec. Different temperature programs were used according to the extraction procedure. All samples (2 µl) were 
injected in splitless mode. Samples from dodecane culture overlays were analyzed using the temperature pro-
gram described in reference32. Briefly, after a 3 min hold at 60 °C, the temperature was increased to 240 °C with a 
gradient of 15 °C/min, concluding with a 10 min hold at 200 °C. The scan range was from 35 to 450 m/z. For the 
analysis of ethyl acetate or pentane extracted and TMS-derivatized samples, the temperature program initiated 
at 60 °C, and the temperature was increased to 200 °C with a rate of 15 °C/min, where it was held for 10 min, and 
then raised at 15 °C/min to 290 °C and held for 20 min. MS data from 50 to 550 m/z were collected during the 
temperature ramp19.
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